Jan. 26 (Bloomberg) -- Momenta Pharmaceuticals Inc. dropped as much as 16 percent after a U.S. appeals court granted Amphastar Pharmaceuticals Inc. a stay pending appeal of a ruling involving generic forms of Lovenox.
Notice of the ruling was posted on the docket of the U.S. Court of Appeals for the Federal Circuit. Momenta has won an order that prevented Amphastar and Watson Pharmaceuticals Inc. from selling a copy of the blood-thinner. The appeal in the case was heard by the Federal Circuit on Jan. 24.
To contact the reporter on this story: Susan Decker in Washington at email@example.com
To contact the editor responsible for this story: Romaine Bostick at firstname.lastname@example.org